Kornimate/medical-research-clean huggingface dataset:
behavior and knowledges of patients enrolled into sioux study

Conditions: Osteoporosis

Summary: the purpose of this study is to contribute to the evaluation of sioux study by adding data about the choices of the observant patients, the mis-observant ones or the protocol deviations.

the adherence to treatment for osteoporosis doesn't exceed 50% after one year. the sioux project about the inter-professional collaboration (attending physician with dispensary pharmacist) developed therapeutic patient education (tpe) plans and created follow-up booklets which were dealt to the patients who have to transmit it to their two medical professionals twice a year during three years one after one. the results after 18 months are encouraging about the improvement of adherence to treatment and about the lifestyle changes.

Eligibility criteria:
inclusion criteria: * patients enrolled into sioux study exclusion criteria: * cognitive troubles which prevent the patient to participate in individual interview
an exploratory study of adr-001 in patients with severe pneumonia caused by sars-cov-2 infection

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2

Summary: safety and efficacy of adr-001 are evaluated in patients with severe pneumonia caused by sars-cov-2 infection.

patients with severe pneumonia caused by sars-cov-2 infection are enrolled to the study. adipose-derived mesenchymal stem cells (ad-mscs) are administered once a week, total four times intravenously. safety and efficacy of ad-mscs are evaluated for 12 weeks after first administer.

Eligibility criteria:
inclusion criteria: * sars-cov-2 infection is confirmed on antigen test or pcr test * pulmonary infiltrative shadow is confirmed on chest x-ray test * mechanical ventilation is being utilized, or acute respiratory failure whose pao2 is not being achieved to 80 mmhg in spite of high-flow oxygen therapy exclusion criteria: * continue treatment for pneumonia before sars-cov-2 infection * sofa score \>= 15 * infection type on dic diagnosis criteria \>= 4 * deep venous thrombosis
acupuncture in herpes zoster neuralgia (acuzoster)

Conditions: Herpes Zoster; Postherpetic Neuralgia; Pain

Summary: symptoms that herald herpes zoster include pruritus, dysesthesia and pain along the distribution of the involved dermatome. the most distressing symptom is typically pain and the most feared complication is postherpetic neuralgia (phn), the persistence of pain long after rash healing. phn is defined as pain persisting more than 3 months after the rash has healed. both, the acute pain associated with herpes zoster and the chronic pain of phn, have multiple adverse effects on health-related quality of life. the primary objective of the trial presented is to investigate whether a 4 week semi-standardised acupuncture is non-inferior (first step) or superior (second step) to (a) the anticonvulsive drug gabapentin and (b) sham laser acupuncture in the treatment of pain associated with herpes zoster in addition to standardised analgesics. secondary objectives include an assessment of the change of sensoric function, of long-term effectiveness, the occurrence of phn and an evaluation of several pain specific questionnaires


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of acute hz * pain intensity \> 30 mm visual analog scale exclusion criteria: * patients with insulin-dependent diabetes mellitus or other diseases influencing the peripheral sensibility (e.g., polyneuropathia, chronic pain syndromes, cutaneous irritations i.e. burns) * patients under age * uncompliance * pregnancy or lactation * surgery within the last 3 month * severe heart/lung/kidney disease * diseases influencing the quality of life * psychiatric diseases (e.g., depression, schizophrenia, dementia) * chronic intake of analgesics, neuroleptics, antidepressants, corticoids, alpha-agonists * acupuncture, transdermal electric neurostimulation or other complementary and alternative medicine treatment within the last 4 weeks * contraindications according to the summary of product informations against analgesic treatment (i.e., metamizol, paracetamol, tramadol, morphine) or the investigational medicinal products (gabapentine, acupuncture needles)

Keywords: herpes zoster neuropathic pain acupuncture randomised controlled trial acute herpes zoster
theta burst stimulation for motor recovery

Conditions: Transcranial Magnetic Stimulation

Summary: repetitive transcranial magnetic stimulation (rtms) is a non-invasive neuromodulation technology. this study will compare efficacy of different doses itbs in combination with inhibitory rtms on motor recovery and cortical excitability in subacute stroke patients.

repetitive transcranial magnetic stimulation (rtms) is a non-invasive neuromodulation technology. high and low frequencies of rtms could modulate the excitability of the cerebral cortex. theta burst stimulation (tbs) has achieved a similar effect to traditional rtms mode. intermittent tbs (itbs) could upregulate cortical excitability of the primary motor cortex (m1) and continuous tbs (ctbs) with inhibitory effect. through modulating the excitability of bilateral hemispheres, rtms could facilitate motor recovery in stroke patients. this study will compare efficacy of different doses itbs in combination with inhibitory rtms on motor recovery and cortical excitability in subacute stroke patients.

Eligibility criteria:
inclusion criteria: * 1.unilateral ischemic or hemorrhagic stroke * 2.stroke within 3 months * 3.medical research council scale for muscle strength in upper limb ≤ 3 * 4.no previous stroke, seizure, dementia, parkinson's disease or other degenerative neurological diseases. * 5.patient could sit over 15 minutes * 6.age over 20 exclusion criteria: * 1.previous stroke, traumatic brain injury, brain tumor * 2.with central nervous system disease (spinal cord injury, parkinson's disease) * 3.any contraindication to rtms (seizure, alcoholism, metal implant, pacemaker) * 4.patients unable to cooperate the treatment * 5.pregnancy * 6.depression
clinical trial to evaluate the addition to an antiretroviral treatment of a probiotic

Conditions: HIV; Premature Aging

Summary: the main purpose of this study is to evaluate a therapy for the inflammaging (premature aging).

it's been demonstrated that the hiv-1 virus is associated to the reduction of the microbiota. some studies suggest that because of this bacterial reduction, the premature aging appears. so this study aims to demonstrate that our probiotic can balance the microbiota as a preventive solution for the inflammaging.

Eligibility criteria:
inclusion criteria: * older than 18 years old. * documented hiv-1 infection. * be in treatment with these antiretrovirals (ini, ip, itinan) during 12 months. * hiv-1 viral titer \<50 copies/ml during 6 months. * cd4\> 500 cells/mm3. exclusion criteria: * treatment with antibiotics. * severe diseases actives. * defining diseases of aids in the previous year. * gut surgery except appendectomy or cholecystectomy. * pregnancy. * any diet deviation (vegans). * other probiotic treatment.

Keywords: hiv-1
phase i pilot study of liver-directed gene therapy for partial ornithine transcarbamylase deficiency

Conditions: Ornithine Transcarbamylase Deficiency Disease

Summary: objectives: evaluate the safety and feasibility of administering recombinant adenovirus containing the ornithine transcarbamylase gene to adults with partial ornithine transcarbamylase deficiency.

protocol outline: this a dose escalation study to estimate the maximum tolerated dose of recombinant adenovirus encoded with the ornithine transcarbamylase gene. patients receive a single dose of virus infused into the liver under fluoroscopic guidance. groups of 3 patients receive successively higher doses of virus; each cohort is observed for safety for 3 weeks before entry of the next group. patients are followed weekly for 1 month, then every 3 months until stable.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- confirmed partial ornithine transcarbamylase deficiency asymptomatic, i.e., at least 1 month since hyperammonemia --prior/concurrent therapy-- not specified --patient characteristics-- no pregnant or nursing women negative pregnancy test required of fertile women

Keywords: inborn errors of metabolism rare disease urea cycle disorder
chinese fpd registry

Conditions: Parkinson Disease

Summary: the purpose of the chinese familial parkinson's disease registry (cfpdr) is to develop a database of patients with familial parkinson's disease (pd) in china.

parkinson's disease (pd) is the second most common disorder among degenerative neurological disease. familial pd (fpd) has its unique clinical feature and genetic basis. we aim to establish a database of fpd,and characterize the clinical feature, genetic basis, environmental factors and their interactions fpd in china. method: 1. clinical feature will be measured by scales and neurological tests.standard scales includes: unified parkinson's disease rating scale(updrs), hoehn-yahr stages, nmss, mmse, pdss(parkinson disease sleep scales),rapid eye movement sleep behaviour disorder questionnaire(rbdq-hk),ess(epworth sleepiness scale),rome iii functional constipation scale，scopa-aut (the scale for outcomes in pd for autonomic symptoms)，pfs(parkinson fatigue scale)，ch-rlsq，hyposmia rating scale(hrs)hamilt depression scale，the 39-item parkinson's disease questionnaire(pdq-39)，freezing of gait scale(fog)，dyskinesia related scales, wearing-off scale(wo) 2. peripheral blood from patients and other members in family will be collected for familial pd genetic testing. 3. the environmental factors are exploded by questionnaires including smoking,drinking, pesticide and heavy metals.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson's disease, and either family history of parkinson's disease (first or second degree family member affected by parkinson's disease) and/or clinical diagnosis of parkinson's disease and their parents are close relatives(first or second degree family member of an index case, affected or unaffected by parkinson's disease). exclusion criteria: * lack of capacity to consent to participate in the project
early oral nutrition in mild acute pediatric pancreatitis

Conditions: Acute Pediatric Pancreatitis

Summary: this is a prospective trial for children with the diagnosis of mild acute pancreatitis admitted to the hospital for continued management. patients will be enrolled in the study within 24 hours of admission/diagnosis and will be allowed an oral diet once enrolled. demographic, laboratory and imaging data done as standard of care will be collected and additional blood work will be sent as part of the study. patients will be followed prospectively with regards to tolerance to oral nutrition, pain, length of stay and complications. the hypothesis is that patients that are able to tolerate early oral nutrition will have shorter length of stays and will be similar in terms of pain score ratings, readmission rates, complications and the need for invasive supplemental nutrition. also patients that are able to tolerate early oral nutrition will have less significant elevation of biochemical markers of pancreatitis severity when compared to patients that do not tolerate early oral nutrition and historical controls.


Eligibility criteria:
inclusion criteria: * diagnosis of acute pancreatitis * enroll within 24 hours of diagnosis * at least 50% of baseline diet must be taken orally exclusion criteria: * evidence of severe pancreatitis * diagnosis of chronic pancreatitis * patients unable to communicate pain or a desire to eat/drink
peritoneal cavity conditioning decreases pain, inflammation and adhesions

Conditions: Endometriosis of the Cul-de-sac; Chocolate Cyst of Ovary; Fibroid/Myoma (Uterus/Cervix)

Summary: full conditioning of the peritoneal cavity during laparoscopic surgery will decrease post-operative pain, inflammation and adhesion formation. full conditioning will decrease an inflammatory response of the peritoneum and decrease pain and adhesion formation.

randomized controlled trial (rct) comparing carbon dioxide to full conditioning (addition of oxygen, nitrous oxide, humidification and temperature control, dexamethasone and hyalobarrier gel) women undergoing laparoscopy for endometriosis, myomectomy or adhesiolysis will be randomized to either group and will be compared for pain (vas scores); inflammation (white blood cells, crp) and adhesions scored by second look laparoscopy.

Eligibility criteria:
inclusion criteria: * women undergoing laparoscopic excision of deep endometriosis (stratum 1), excision of endometrioma's (stratum 2) or excision of uterine myoma's (stratum 3) since this is severe surgery, associated with severe postoperative adhesions and since for most of these women fertility is important and hence the second look laparoscopy can be beneficial. * signed informed consent exclusion criteria: * women with a pre-existing condition increasing the risk of surgery such as clotting disorders, heart or lung impairment etc.-any condition that might interfere with inflammatory parameters such as immunodeficiency, chronic inflammatory disease as crohn's disease. * pregnancy * conditions associated with chronic pain as peripheral neuropathy, pathology of the vertebral column and osteo-articular disease. conditions causing acute pain e.g. abdominal trauma * a known allergic reaction to hyalobarrier gel endo® * a bowel lesion requiring a single or double layer suture. (given that for none of the anti-adhesion barriers safety has been proven following bowel lesions and suture)

Keywords: women undergoing laparoscopic surgery
safety profile of insulin like growth factor-1 (igf-i) administration in adolescents

Conditions: Anorexia Nervosa

Summary: the purpose of this study was to determine whether giving insulin like growth factor-i (igf-i) to adolescent low weight girls is safe and whether this increases levels of bone formation markers.

adolescents with anorexia nervosa (an) are at high risk for low bone mineral density at a time when healthy adolescents are rapidly accruing bone, with implications for peak bone mass and fracture risk in later life. they are also deficient in insulin-like growth factor i (igf-i), the bone trophic factor made in the liver in response to growth hormone (gh), despite elevated levels gh. it is possible that deficiency of igf-i, a hormone very important for the maintenance of skeletal integrity, may contribute to the severe osteopenia seen in an. the physiologic effects of rhigf-i treatment in adolescents with an had not been studied. the goal of this proposal was to investigate the acute effects of rhigf-i on bone metabolism in adolescent girls with an. specific aim: it was hypothesized that adolescent an patients, being igf-i deficient, would respond to exogenously administered rhigf-i with elevations in biochemical indices of bone turnover. therefore, rhigf-i was administered to an patients by subcutaneous injection over 10 days with concomitant measurement of indices of bone turnover, and calcium regulatory hormones.

Eligibility criteria:
inclusion criteria: * adolescent girls with anorexia nervosa 12-18 years old exclusion criteria: * pregnancy or nursing * hematocrit \< 30%, k \< 3 mmol/l * any illness (other than anorexia nervosa) known to affect bone and mineral metabolism such as diabetes, alcoholism, untreated hypo- or hyperthyroidism, or hyperparathyroidism * history of use of any medicine, such as corticosteroids, known to affect bone density. subjects who were on estrogen were still eligible to participate in the study.

Keywords: adolescents anorexia nervosa (an) bone formation markers insulin like growth factor-1 (igf-i)
mil60 versus bevacizumab in patients with treatment-naïve non-squamous non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: this randomized, double-blind, multi-center phase 3 study is aimed to compare the efficacy and safety of mil60 with bevacizumab as first-line treatment when combined with standard chemotherapy (paclitaxel/carboplatin) in treatment-naive patients with advanced or recurrent non-squamous nsclc.

this is a multicenter, double-blind, randomized, parallel-group phase 3 clinical trial evaluating the efficacy and safety of mil60 plus paclitaxel and carboplatin versus bevacizumab plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous nsclc.the primary objective of the study was to compare the objective response rate according to recist 1.1 of mil60 in combination with paclitaxel plus carboplatin and bevacizumab plus paclitaxel plus carboplatin in the treatment of advanced or recurrent non-squamous nsclc subjects.

Eligibility criteria:
inclusion criteria: * signed inform consent form(icf) * aged 18-75 years, male or female * histologically or cytologically documented inoperable, local advanced (stage iiib), metastatic (stage iv), or recurrent non-squamous nsclc * at least one measurable lesion according to response evaluation criteria in solid tumors（recisit） v 1.1 * eastern cooperative oncology group(ecog) performance status of 0 or 1 * life expectancy ≥ 12 weeks * patients of childbearing potential must agree to use effective contraceptive measures during study treatment and for 6 months after receiving last study treatment exclusion criteria: * mixed non-small cell lung cancer with squamous cell carcinoma component, or small cell carcinoma * patients with known anaplastic lymphoma kinase（alk） or c-ros oncogene 1 receptor tyrosine kinase （ros1）rearrangement * history of hemoptysis within 3 months prior to screening with blood volume more than 2.5 ml * evidence of tumor invading major blood vessels on imaging * patients with brain metastasis, spinal cord compression or carcinomatous meningitis history * uncontrolled hypertension, prior history of hypertensive crisis and hypertensive encephalopathy * clinically significant cardiovascular disease but not limited to active infections; unstable angina; stroke or transient cerebral ischemia; myocardial infarction; congestive heart-failure; serious cardiac arrhythmia, hepatic, renal or metabolic disease requiring medication during the study * history of radical radiotherapy to the thorax within 6 months * serious, non-healing wound, active ulcer, or untreated bone fracture, or major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of the study * recent or current treatment with aspirin or other non-steroidal anti-inflammatory drugs (nsaid) known to inhibit platelet function within 10 days prior to first dose of study treatment * recent or current treatment with anticoagulants or thrombolytic agent within 10 days prior to first dose of study treatment
autologous fresh whole blood and coagulation following cardiopulmonary bypass in infants

Conditions: Congenital Heart Defects

Summary: dilution of blood caused by cardiopulmonary bypass (the heart-lung machine) during open heart surgery is associated with decreased concentrations in the blood of coagulation factors. this can be extreme in infants because of their small blood volumes and can lead to impairment of the normal blood clotting mechanism and excessive bleeding after the operation. transfusion of fresh whole blood has been shown to be an effective treatment because fresh blood is rich in coagulation factors. however, it is difficult to obtain truly fresh blood from a blood bank. we hypothesized that fresh blood drawn from the patient and given back after cardiopulmonary bypass would improve the clotting mechanism. in our study, the infants in the treatment group have some of their own fresh blood removed after they are anesthetized for the operation and before they are placed on cardiopulmonary bypass. this blood is then given back to them after completion of cardiopulmonary bypass. infants in the control group will not have their own blood removed but will undergo cardiopulmonary bypass. we will compare the two groups by drawing blood samples that measure coagulation tests.


Eligibility criteria:
inclusion criteria: * undergoing non-complex open heart surgery * diagnosis of congenital heart disease * no previous open heart surgery * weight 15 kg or less

Keywords: dilutional coagulopathy
predicting readmissions using omics, biostatistical evaluate and artificial intelligence

Conditions: Heart Failure

Summary: this study is a prospective registry that aims to predict readmissions in patients with heart failure, using -omics, machine learning, patient reported outcomes, clinical data and other high-dimensional data sources.

there is substantial need to better predict outcomes across the spectrum of heart failure (hf) phenotypes in order to provide more efficient care with greater precision. specifically, no validated methods have been adopted to predict outcomes reflecting transitions in health status across the continuum of hf and changes in cardiac function. a key transition is hospitalization - either readmission or de novo cardiovascular hospital admission. this is a major unmet health care need, to be able to better predict who will require hospital admission. novel contributions of biomarkers, -omics, remote patient monitoring, and artificial intelligence (ai). it is anticipated that prediction of readmission and many other outcomes will be further improved by measurement of circulating biomarkers and by incorporating methods from ai including machine learning and probabilistic generative models that can incorporate the lens of how physicians and patients think. machine learning that incorporates many different types of data, including physician interpretation and a broad array of biomarker/-omics molecular information can lead to significant improvements in predictive accuracy. novel multimarker strategies coupled with machine learning may enable the ability of physicians to predict a range of outcomes (e.g., transitions in hf health status and lvef) and refine clinical prediction models. furthermore, the investigators will collect patient data, including patient reported outcome measures (proms), and physiological data (e.g. heart rate, blood pressure, and daily weights data) and integrate these data points into predictive models. the investigators will use the proms obtainable using medly as a predictor of hospitalization, and as an outcome. in this proposal, the investigators will take advantage of recent advances in both deep and high throughput proteomics technologies to perform high-resolution analyses. these novel factors can be integrated into new electronic algorithms to improve hf care in the population.

Eligibility criteria:
inclusion criteria: * any patient aged 18 years or older admitted to hospital or seen in the emergency department with heart failure defined clinically * the diagnosis will be guided by the framingham criteria for hf and/or bnp. a bnp \>400 will be defined as definite heart failure and bnp 100-400 classified as possible heart failure. * provides informed consent exclusion criteria: * patients who cannot communicate due to dementia or severe cognitive deficits * non-ontario residents * nursing home residents * those who are not discharged home but are discharged to a skilled nursing facility (long-term care or chronic institution) * those who are unable to communicate who do not have a proxy (e.g. spouse or close family member) to facilitate communication with the patient.